Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
OABI 
OmniAb Inc. (OABI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
10/29/2025: OABI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $8.5
1 Year Target Price $8.5
| 6 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -42.36% | Avg. Invested days 22 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/29/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 223.13M USD | Price to earnings Ratio - | 1Y Target Price 8.5 |
Price to earnings Ratio - | 1Y Target Price 8.5 | ||
Volume (30-day avg) 8 | Beta 0.93 | 52 Weeks Range 1.22 - 4.87 | Updated Date 10/29/2025 |
52 Weeks Range 1.22 - 4.87 | Updated Date 10/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.61 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -275.83% | Operating Margin (TTM) -416.19% |
Management Effectiveness
Return on Assets (TTM) -13.7% | Return on Equity (TTM) -22.84% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 211936194 | Price to Sales(TTM) 9.69 |
Enterprise Value 211936194 | Price to Sales(TTM) 9.69 | ||
Enterprise Value to Revenue 9.2 | Enterprise Value to EBITDA -10.62 | Shares Outstanding 143955400 | Shares Floating 85991521 |
Shares Outstanding 143955400 | Shares Floating 85991521 | ||
Percent Insiders 14.75 | Percent Institutions 58.31 |
Upturn AI SWOT
OmniAb Inc.
Company Overview
History and Background
OmniAb, Inc. was formed through the business combination of Ligand Pharmaceuticals Incorporated's (Ligand) OmniAb advanced antibody discovery technology and Avista Public Acquisition Corp. II (APAC II) in 2022. OmniAb leverages innovative transgenic animal platforms and sophisticated screening technologies to enable the discovery and development of next-generation therapeutics.
Core Business Areas
- Antibody Discovery Technology: OmniAb licenses its antibody discovery platform, generating revenue through upfront payments, milestone payments, and royalties on the sales of drugs developed using its technology.
- Therapeutic Antibody Programs: OmniAb has a diverse set of partners leveraging its platform for a variety of therapeutic targets, addressing oncology, autoimmune disorders, and infectious diseases.
Leadership and Structure
Dr. Matt Foehr is the Chief Executive Officer. The company operates with a functional organizational structure, including research and development, licensing, business development, and finance departments.
Top Products and Market Share
Key Offerings
- OmniAb Antibody Discovery Platform: This platform includes several transgenic animals (OmniRat, OmniMouse, OmniFlic, OmniChicken, OmniTaur, OmniFish) which generate fully human antibodies. It is the core revenue generator through licensing agreements. The platform competes with traditional hybridoma technology and other antibody discovery platforms such as those offered by Regeneron (VelociSuite), AbCellera (AI-powered discovery), and Adimab (Yeast display). Market share is difficult to pinpoint precisely but growing rapidly based on partnerships made with top 10 pharma partners since launch. Revenue generated from milestone payments and royalties will lag behind the initial licensing revenues.
Market Dynamics
Industry Overview
The antibody therapeutics market is a large and growing market driven by the increasing prevalence of chronic diseases, advancements in antibody engineering, and the demand for targeted therapies. The market is highly competitive with many companies developing new antibody-based drugs.
Positioning
OmniAb is positioned as a leading provider of antibody discovery technology. Its competitive advantage lies in its robust transgenic animal platforms and strong intellectual property portfolio. OmniAb is focused on partnering with pharmaceutical and biotechnology companies to accelerate the development of novel antibody therapeutics.
Total Addressable Market (TAM)
The antibody therapeutics market is projected to reach hundreds of billions of dollars by the late 2020s. OmniAb's positioning as a discovery platform gives it access to a significant portion of this TAM, as its technology can be applied to a broad range of therapeutic targets.
Upturn SWOT Analysis
Strengths
- Leading antibody discovery platform
- Diverse portfolio of transgenic animals
- Strong intellectual property
- Experienced management team
- Existing partnerships with top Pharma
- Proven Revenue Growth
Weaknesses
- Reliance on partners for downstream drug development success
- Relatively high research and development expenses
- Potential for competition from new antibody discovery technologies
Opportunities
- Expansion into new therapeutic areas
- Strategic collaborations with pharmaceutical companies
- Development of new antibody engineering technologies
- Expansion into other large molecule targets.
- Increasing adoption of AI/ML in drug discovery
Threats
- Competition from established antibody discovery platforms
- Patent challenges
- Regulatory hurdles
- Failure of partners to successfully develop drugs using OmniAb technology
- Changes in the pharmaceutical industry landscape
Competitors and Market Share
Key Competitors
- REGN
- ABCL
Competitive Landscape
OmniAb's platform is designed to accelerate the drug discovery process while competing with the larger discovery houses. The platform's advantages and disadvantages depend on specific partnerships.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is dependent upon the closing of the merger and the execution of new partnerships.
Future Projections: Future projections depend on the successful execution of the growth strategy and the successful advancement of partner programs through clinical trials and commercialization.
Recent Initiatives: Recent initiatives include expansion of partnerships with pharmaceutical companies and development of new technology.
Summary
OmniAb is an antibody discovery platform company that partners with pharmaceutical companies to develop novel antibody therapeutics. The company's strength lies in its technology and partnerships, but its success depends on the clinical progress and commercialization of partner programs. Key weaknesses are its reliance on partners and potentially high expenses. Future growth depends on new partnerships and technology.
Similar Stocks
Sources and Disclaimers
Data Sources:
- OmniAb Inc. SEC Filings
- Company Website
- Industry Reports
Disclaimers:
The data provided is for informational purposes only and should not be considered investment advice. Market data is based on estimations and assumptions and may not be perfectly accurate. Investment decisions should be made based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About OmniAb Inc.
Exchange NASDAQ | Headquaters EmeryVille, CA, United States | ||
IPO Launch date 2022-11-02 | President, CEO & Director Mr. Matthew W. Foehr | ||
Sector Healthcare | Industry Biotechnology | Full time employees 114 | Website https://www.omniab.com |
Full time employees 114 | Website https://www.omniab.com | ||
OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners' drug development efforts. Its OmniAb platform's Biological Intelligence powers the immune systems of its proprietary and engineered transgenic animals to create optimized antibody candidates for human therapeutics. The company's animal-based technologies include OmniRat, OmniChicken, and OmniMouse, which have been genetically modified to generate antibodies with human sequences; OmniFlic, a bispecific rat and OmniClic, a bispecific chicken are designed for discovery of bispecific antibody applications; OmniTaur, which provides cow-inspired antibodies with unique structural characteristics for challenging targets; OmnidAb, an in vivo platform for the discovery of single-domain antibodies based upon a human VH scaffold; and OmniDeep, a suite of in silico, an artificial intelligence (AI) and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. The company has an agreement with mAbsolve Ltd. for its Fc-silencing platform technology to incorporate the STR technology into antibodies that have been generated using OmniAb's antibody discovery platform. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.